Tagatose, a rare natural sugar sold as a low-calorie sweetener, tastes like table sugar but supplies far fewer calories. Its clearest effect is a smaller blood sugar and insulin rise after carbohydrate meals; a year of use modestly improved long-term blood sugar control in type 2 diabetes, while evidence in people with normal blood sugar is limited to single meals. Gas, bloating and diarrhea set the practical ceiling on intake. (Full Review)

Protocol

Trial regimen

15 g three times daily

With meals in 125–250 mL water; reduced to 10 g or 5 g for digestive effects; used for a year in type 2 diabetes

Lower-dose regimen

5–7.5 g three times daily

With meals; 5 g was the minimum dose lowering HbA1c and 7.5 g gave the largest effect in a six-month dose-finding trial

Single or split dosing

Split across meals

Each dose acts on the carbohydrate-containing meal it accompanies; splitting improves digestive tolerance

Time to effect

Post-meal glucose

Same meal

Glucose blunting occurs with the meal the dose accompanies

HbA1c

By 2 months

Changes appeared by two months in the phase 3 trial and grew through 10 months

Benefits

High: Blunted post-meal blood sugar and insulin; lower HbA1c and fasting glucose in type 2 diabetes

Low: Reduced appetite and body weight; improved blood lipids

Speculative: Lower dental cavity risk; prebiotic support of gut bacteria; antioxidant and anti-inflammatory effects

Contraindications

Hereditary fructose intolerance (confirmed ALDOB mutation or aldolase B deficiency)

Gout with serum uric acid above 6 mg/dL despite therapy or two or more flares per year

IBS meeting Rome IV criteria or diagnosed SIBO, unless tolerance is tested at low doses

Pregnancy and breastfeeding, beyond ordinary food amounts

Insulin- or sulfonylurea-treated diabetes with recent level 2 hypoglycemia (glucose below 54 mg/dL) and no glucose monitoring

Advanced chronic kidney disease (eGFR below 30 mL/min/1.73 m²)

Key Interactions

Glucose-lowering drugs (insulin; sulfonylureas such as glipizide, glimepiride): Caution

Alpha-glucosidase inhibitors (acarbose, miglitol): Caution

Metformin and GLP-1 receptor agonists (semaglutide, tirzepatide): Monitor

Uric-acid-raising drugs (thiazide and loop diuretics such as hydrochlorothiazide and furosemide; low-dose aspirin): Monitor

Urate-lowering therapy (allopurinol, febuxostat): Monitor

Over-the-counter laxatives (polyethylene glycol, lactulose, magnesium hydroxide): Caution

Polyols (sugar alcohols) and fermentable fibres (erythritol, xylitol, sorbitol, inulin): Caution

Glucose-lowering supplements (berberine, allulose, cinnamon extract): Monitor

Fructose-rich foods and alcohol: Monitor

Low-FODMAP diet (used for IBS): Caution

Risk & Side Effects

High: Gastrointestinal intolerance

Low: Raised uric acid; unfavourable triglyceride and HDL shift

Speculative: Liver glycogen accumulation; harm in hereditary fructose intolerance; low blood sugar with glucose-lowering drugs

Monitoring

Marker	Target	Why
HbA1c	4.8–5.3%	Tracks 3-month glucose control
Fasting glucose	75–90 mg/dL	Detects glucose-lowering effect
Fasting insulin	2–6 µIU/mL	Gauges insulin demand
Post-meal glucose (CGM)	Peak below 140 mg/dL; back to baseline within 2–3 hours	Confirms the meal-level effect
Serum uric acid	3.5–5.5 mg/dL	Monitors fructose-like urate effect
Lipid panel (LDL-C, HDL-C, triglycerides)	LDL-C below 100 mg/dL; HDL-C above 50 mg/dL; triglycerides below 100 mg/dL	Checks for lipid shifts
ALT	Below 25 U/L	Screens for liver strain
Body weight and waist circumference	No established target; track change from own baseline	Tracks energy-balance effect

Cadence: Baseline before starting; 2 weeks (tolerance and, if medicated, glucose); 3 months (HbA1c, fasting glucose and uric acid); then every 6–12 months (full panel)

Qualitative Assessment

Digestive symptom diary (gas, bloating, stool form on the Bristol Stool Scale) during titration
Post-meal energy and absence of afternoon slumps
Satiety and sweet cravings across the day
Joint pain or swelling suggestive of gout
Dental plaque and gum health at routine dental visits

Tagatose for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment